According to the AUA/SUFU guidelines, ER formulations — if available — should preferentially be prescribed over IR formulations because of lower rates of dry mouth.
The guidelines state that because OAB is a chronic condition and treatment with antimuscarinics generally is required long-term, medication tolerability is critical to obtaining patient compliance. Adverse drug events, particularly dry mouth, are the major reasons that patients do not adhere with antimuscarinic therapy; thus, choosing the formulation with the lowest likelihood of adverse events may improve adherence. In addition, adherence with a once-daily treatment has been shown to be greater than with medications that are taken more than once a day.
The guidelines also note that if a patient has good symptom control and tolerable side effects on an IR formulation, then there is no need to change to an ER formulation.
Learn more about the pharmacologic management of OAB.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Bradley Schwartz. Fast Five Quiz: Overactive Bladder Pharmacologic Management - Medscape - Feb 26, 2021.